Inactive Instrument

Threshold Pharmaceuticals, Inc. Stock price Nasdaq

Equities

US8858072064

Biotechnology & Medical Research

Sales 2023 * 58.06M Sales 2024 * 22.73M Capitalization 12.68M
Net income 2023 * -11M Net income 2024 * -28M EV / Sales 2023 * 0.22 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 0.56 x
P/E ratio 2023 *
-0.9 x
P/E ratio 2024 *
-0.69 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 94.84%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 52 99-12-31
Director of Finance/CFO 49 09-12-31
Chief Operating Officer 53 16-12-31
Members of the board TitleAgeSince
Chief Executive Officer 52 99-12-31
Chairman 69 17-07-31
Director/Board Member 79 17-07-31
More insiders
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted biologic therapeutics. Its drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragment (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized Shiga-like toxin-A subunit (SLTA) and a class I antigen derived from the human cytomegalovirus (HCMV). pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 focuses on targeting CD38. CD38 is a single-chain type II transmembrane glycoprotein that is expressed by a variety of hematologic cells in an activation- and differentiation-dependent manner.
More about the company
  1. Stock
  2. Equities
  3. Stock Molecular Templates, Inc.
  4. Stock Threshold Pharmaceuticals, Inc. - Nasdaq